
Journal of Clinical Tuberculosis and Other Mycobacterial Diseases 5 (2016) 4-7



Contents lists available at ScienceDirect

Journal of Clinical Tuberculosis and Other Mycobacterial Diseases



journal homepage: www.elsevier.com/locate/jctube

Tuberculosis screening at a diabetes clinic in the Republic of the Marshall Islands



R.M. Trinidad^a, R. Brostrom^{b,*}, M.I. Morello^c, D. Montgomery^c, C.C. Thein^d, M.L. Gajitos^d, A. Heetderks^b, T. Chorba^b

^a Ministry of Health, Ebeye, Marshall Islands

^b Centers for Disease Control and Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Division of Tuberculosis Elimination, Atlanta, GA, United States

^c Centers for Disease Control and Prevention, Office of Surveillance, Epidemiology, and Laboratory Services, Atlanta, GA, United States

^d Kwajalein Atoll Healthcare Bureau, Kwajalein, Marshall Islands

ARTICLE INFO

Article history: Received 1 April 2016 Revised 12 October 2016 Accepted 21 October 2016

Keywords: Tuberculosis Diabetes Pacific Islands Bi-directional screening

ABSTRACT

Setting: Tuberculosis (TB) and diabetes mellitus (DM) are prominent public health problems in the Republic of the Marshall Islands, a small island nation with high rates of tuberculosis and diabetes. *Objective:* Evaluate the rate of active and latent TB in a Pacific Island DM clinic.

Design: In one DM clinic on the island of Ebeye, 213 adult patients aged 27–86 years completed tuberculin skin testing and TB work-up between April 2010 and March 2012.

Results: Screening for TB led to the diagnosis of 77 patients with TB infection and 11 patients with TB disease. From these data, the prevalence of TB disease among DM patients in the clinic exceeded 5% (95% CI 2.2%–8.1%). All patients who completed TB screening were at high risk of TB disease, and those with DM aged \leq 50 years had a higher risk of TB disease than those with DM over age 50 (RR 3.1, C.I. 1.0–9.7, p = 0.05).

Conclusion: The experience at the Ebeye Diabetes Clinic demonstrates that screening DM patients for TB can identify significant rates of TB infection and TB disease, and should be considered for other settings with a high background TB incidence. Further assessment of TB risks should explore age, gender, and level of diabetes control.

© 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

1. Introduction

Tuberculosis (TB) and diabetes mellitus (DM) are highly prevalent in the U.S. Affiliated Pacific Islands (USAPI) which include American Samoa, Commonwealth of the Northern Mariana Islands, Federated States of Micronesia, Guam, Palau, and Republic of the Marshall Islands (RMI). Despite recent improvements in regional TB control, the reported 2013 TB incidence rate in the USAPI was 76.6 cases per 100,000 persons, compared to the overall U.S. national TB case rate (for the 50 States and the District of Columbia, exclusive of territories) of 3.0 per 100,000 [1]. The prevalence of TB in the RMI is the highest in the USAPI at 215 per 100,000 [1]. To add to this, the prevalence of type 2 diabetes among adults in the Marshall Islands is 41%, one of the highest reported DM rates in the world [2].

* Corresponding author. E-mail address: hld4@cdc.gov (R. Brostrom). In response to growing awareness of the convergence of DM and TB in USAPI, the Pacific Island TB Controllers Association (PITCA) has adopted a set of clinical practice standards, the USAPI Standards for the Management of Tuberculosis & Diabetes [3]. These standards were proposed in 2006, were reviewed by regional experts, and were formally adopted by USAPI public health authorities in December 2010. In parallel to the overarching WHO Collaborative Framework for Care and Control of Tuberculosis and Diabetes [4], the USAPI TB-DM Standards include recommendations for bidirectional TB and DM screening, strategies for glucose control during TB treatment, DM education during TB treatment, and clinical practices to improve TB-DM patient outcomes.

The USAPI TB-DM Standards are being followed in several locations, including the RMI. Ebeye is a remote island of 9614 people in RMI's Kwajalein Atoll in the North Pacific, and it represents one of two population centers in RMI [5]. This study assesses the impact of TB screening in Ebeye among DM patients presenting for routine DM care. The screening paradigm used by the program is

http://dx.doi.org/10.1016/j.jctube.2016.10.001

2405-5794/© 2016 Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).



Fig. 1. Tuberculosis (TB) screening results among people with diabetes mellitus, Ebeye Island, 2010–2012 (N = 353).

described, and results of TB screening for finding latent TB infection (LTBI) and TB disease are discussed.

2. Study population and methods

Ethics approval was obtained from the Institutional Review Board (IRB) in the RMI Ministry of Health. The study also underwent ethical review at the Centers for Disease Control (CDC) and was determined to be research that was exempt from CDC IRB review on the basis of this being limited to a program evaluation activity.

Over a 24-month period between April 2010 and March 2012, 353 DM patients were offered a tuberculin skin test (TST). All testing was done at the Ebeye Diabetes Clinic as part of routine DM management. TB program staff visited the weekly half-day DM clinics to provide TB skin-testing. TB staff encouraged DM patients to participate in TB screening, but patient participation was voluntary.

Clinic nurses administered TSTs and recorded results in the DM clinic logbook and patient records. Patients were scheduled to return to the DM clinic 48-72 h later for skin test interpretation. Patients with a $TST \geq 10\,mm$ were referred to the Ebeye TB Clinic for chest x-ray (CXR) and further examination. The Ebeye TB clinician interpreted the CXR and, if consistent with TB disease, ordered sputum for acid-fast bacillus (AFB) smear microscopy in Ebeve. Sputum specimens were also sent to Diagnostic Laboratory Services in Honolulu for AFB culture. Drug susceptibility testing (DST) was obtained on all samples with a positive Mycobacterium tuberculosis culture. Spoligotype and 24-locus Mycobacterial interspersed repetitive units (24-locus MIRU-VNTR was performed on culture confirmed TB isolates that were submitted using the National Tuberculosis Genotyping Service [6]. Follow-up and management for TB were directed through the Ebeye TB Program. Preventive treatment (principally with 9 months of isoniazid) was offered to patients with diabetes who were diagnosed with LTBI.

For patients completing TB screening, rates of active TB were compared for patients age \leq 50 years and those > 50 years old using Epi-Info 7 [7] to obtain the risk ratio (RR) and the 95% confidence interval (CI); Fischer's two-tailed exact test was used to determine the probability [8]. The significance level for statistical analyses was $p \leq 05$.

3. Results

A diagram of the screening methodology is depicted in Fig. 1. A total of 353 patients with DM aged 27–86 years received a TST from April 2010 to March 2012. Of the total, only 213 (60%) had the TST read and documented. Among those who completed initial TB screening, 88 (41%) had a positive result, i.e., TST induration \geq 10 mm. All these patients underwent CXR, and those with abnormal CXR findings underwent sputum collection for acid-fast bacillus (AFB) smear and culture. Among the 88 patients with a posi-

Table 1

Tuberculosis (TB) screening compliance among adults with diabetes mellitus by gender and age, Ebeye Island, 2010–2012 (N = 353).

Category	Completed TB screening	Did not complete TB screening	p value
Number	213	140	-
Age	56.4	54.7	p = 0.11
% Male	32%	22%	p = 0.04

tive TST result, 11 cases of TB disease and 77 cases of LTBI were diagnosed. The isolate from one patient was multi-drug resistant (MDR) TB and the rest of the isolates were susceptible to isoniazid, rifampin, ethambutol and pyrazinamide. Five of the 11 cases (45%) were smear positive and six of the TB cases (54%) were culture positive. Genotype results were available for three out of the six (50%) culture positive cases, and all three had the same Lineage 2 (East-Asian, formerly known as Beijing) genotype (GENType G00017) [9].

Of the five culture-negative cases, 4 (36%) were clinically diagnosed with radiographic changes. Overall, 10 cases were pulmonary TB and one case (9%) was both pulmonary and extrapulmonary TB. From this screening effort, the rate of TB disease among DM patients on Ebeye was 5200 per 100,000 (5.2%; 95% CI 2.2%–8.1%), based on 11 TB cases identified and treated from among the 213 patients who completed the initial screening.

Differences in patient characteristics among those who completed TST screening and those who failed to complete TST screening are listed in Table 1. There was no difference in age between the compliant and non-compliant groups, but the percentage of males who completed screening was significantly higher than females.

Further assessment of the TB case rate among patients with DM on Ebeye reveals an association with age among the 210 individuals who completed screening and for whom age data were available (Table 2). Although TB disease was highly prevalent among all adults who completed screening (11/210, or 5200 per 100,000), adults with DM \leq 50 years of age had greater prevalence (6/56, or 10,700 per 100,000) than those >50 years (5/154, or 3200 per 100,000) (RR 3.1, C.I. 1.0–9.7, p = 0.05).

4. Discussion

In the Ebeye Diabetes Clinic over a 2-year period, 213 patients were tuberculin skin tested, which resulted in diagnosing 77 with LTBI and 11 with TB disease. Recent reviews have underscored the synergistic effect of TB and DM, particularly the effect of DM on progression of TB infection to TB disease, the complexity of treatment when both diseases are present, and the potential value of bidirectional screening [10]. Systematic reviews and meta-analyses of observational studies have demonstrated a relative risk of TB disease developing in DM patients of 3.1 in populations with high

Table	2
-------	---

Results of tuberculosis (TB) screening in among adults with diabetes mellitus by gender and age, Ebeye Island, 2010-2012 (N = 353).

	Completed TB screening	$TST \ < 10 \ mm$	$TST \geq \! 10 mm$	Latent TB	Active TB	p value*
All Age ≤ 50	213 56	125 (59%) 31 (55%)	88 (41%) 25 (45%)	77 (35%) 19 (34%)	11 (5.2%) 6 (10.7%)	RR 3.1
Age > 50	154	91 (59%)	63 (41%)	57 (37%)	5 (3.2%)	p = 0.05 (1.0-9.7)
Males	69	38 (55%)	31 (45%)	26 (38%)	5 (7.2%)	RR 1.7 $p = 0.28$
Females	144	87 (60%)	57 (40%)	51 (35%)	6 (4.2%)	(0.5–5.4)

 * Probabilities refer to rate of TB disease comparing persons ${\leq}50$ years with persons ${>}50$ years, and comparing males with females.

TB incidence, as well as a greater prevalence of DM among TB patients [10–12].

DM is exceptionally common among Pacific Islanders. Urbanization, increasing poverty, a westernized diet, and physical inactivity have been implicated [13,14]. Based upon the overwhelming incidence of DM and other non-communicable diseases, several Pacific Island nations have officially declared national health disasters [15]. Unfortunately, the burden of DM is predicted to increase dramatically in low-income and middle-income countries over the next two decades, as the result of population growth, aging, dietary changes, and continued physical inactivity [16]. For the Pacific, this study is consistent with an impact of DM on local TB incidence rates, and it underscores the necessity of TB and DM program integration in efforts to achieve long-term TB control.

In different settings, the observed strength of association between TB and DM varies considerably, based upon the local prevalence of each disease [10–17]. Although the number of patients with TB was small, this study revealed high rates of TB disease among patients awaiting routine care in the Ebeye DM Clinic over a 2-year period. The more than 5% rate of TB disease over a 2-year period among DM patients in Ebeye is alarming, but prior reports from other high TB-incidence countries have shown similar findings [18,19].

The task of stratifying TB risk among people with diabetes is essential for successful implementation of bidirectional screening. A recent study from southern Mexico determined the risk for progression to TB disease among persons with DM to be inversely related to age [12]. For this study, the risk of TB disease among persons with DM was high for all age groups, but further evaluation demonstrated the risk for TB disease was significantly higher in persons \leq 50 years old than it was for persons over age 50.

Overall, the observed rate of TB disease among those who completed TB screening in the Ebeye DM clinic over a 2-year period was more than 20 times higher than that reported for the RMI general population in 2012 (5200 vs. 215 per 100,000) [1]. It is likely that some of the difference can be explained by the presence of diabetes as well as the active TB case-finding process in this high-incidence setting.

Genotyping data were used to assess the possibility that high rates of TB in the Ebeye DM clinic represented an actual DM clinicassociated outbreak, rather than an overall high rate of TB among adults with diabetes in Ebeye. Only three of these TB cases were genotyped, but all three shared the same genotype (G00017), raising the possibility of a localized cluster of TB cases related to attendance at the DM clinic. However, there are limitations when interpreting genotyping data for identifying TB clusters in the US Pacific, because many common Lineage 2 (East Asian) strains are not well differentiated. The G00017 strain is the most frequently reported genotype in the United States Affiliated islands [1]. Among all genotypes found in the Marshall Islands in 2010 and 2011, this same genotype accounts for 57% (68/120) of TB cases. Similar clustering among East Asian strains, possibly related to on-going transmission, has been reported in Kiribati, a neighboring Pacific Island group [20].

Screening persons who had DM with a TST substantially added to overall TB case finding efforts for the RMI TB Program. Active TB screening in persons with DM can lead to earlier TB diagnosis, and may lead to improved TB treatment outcomes and less transmission of TB. Additional research is underway to evaluate TB presentation and treatment outcomes among persons with diabetes in the USAPI.

This evaluation had several limitations. First, although the TB case rate was high, the number of cases was small. As other US-API jurisdictions progress towards full implementation of the US-API TB-DM Standards, it may be possible to pool results of several island groups for a more robust analysis. Additionally, there was no assessment of the degree of diabetes control relative to TB screening outcomes among the patients. Other studies have found that the risk for progression to TB disease among DM patients with LTBI was strongly correlated with overall glucose control as measured by hemoglobin A1c, or the presence of diabetic complications [21,22]. Pacific programs are working to characterize the degree of diabetes control at the time of TB diagnosis and incorporate the results into routinely collected surveillance data. Third, as noted, genotyping data were only available on three of the cases; although sharing the same genotype commonly found in the RMI, these isolates were not subjected to whole genome sequencing that would give a better indication as to whether these cases were related through recent transmission.

Finally, there are two issues with the use of TST for initial TB screening. While the TST is the only currently available test for the diagnosis of latent TB, the TST does not perform well in a patient with active TB disease and can miss up to 30% of prevalent cases [23]. Operationally, almost 40% of the patients who received a TST did not return for skin test reading, and consequently were not included in the analysis. Preliminary analysis indicated that males were significantly more likely to complete initial TB screening, and Table 2 indicated that males tended to have higher TB rates than females. Additional bias in the results may have also introduced depending on whether patients who were unable to complete the TST reading were more likely to have a negative TST. Other active case finding methodologies have been used in DM clinics to improve success with TB screening [24]. Future implementation of the USAPI TB-DM Standards should focus on strategies to increase completion of TST readings among people with DM, with consideration for another strategy that is more sensitive for active TB, such as periodic chest X-ray.

5. Conclusions

The results from TB screening with TST in the Ebeye DM Clinic underscore the importance of TB-DM screening advocated by the WHO Framework and the USAPI TB-DM Standards as an opportunity for TB case-finding as well as treatment of LTBI in this highrisk group. Improved integration of TB and DM programs with continued implementation of USAPI TB-DM Standards can contribute to reducing the disparity in TB incidence between the USAPI and other U.S. jurisdictions.

Continued program collaboration between TB and DM programs will help to integrate once-vertical public health programs, and shift programs towards enhanced patient-centered care, possibly leading to improved patient outcomes for those with TB disease. As profound dietary and lifestyle changes continue to add significantly to the global burden of DM, other countries with high TB rates may benefit from adapting policies consistent with the WHO Collaborative Framework for Care and Control of Tuberculosis and Diabetes and from implementing standards and clinical guidelines similar to the USAPI Standards for the Management of Tuberculosis & Diabetes.

Acknowledgments

The Curry International Tuberculosis Center (CITC) in California, the Pacific Chronic Disease Coalition, the Australian Respiratory Council, and the Pacific Islands Health Officers Association (PI-HOA) are all acknowledged for their many contributions and longterm collaboration with the Pacific Island TB Controllers Association (PITCA). The authors are also grateful for the genotyping expertise provided by Smita Ghosh from CDC.

References

- Reported Tuberculosis in the United States, 2013. Atlanta, GA: U.S. Department of Health and Human Services, CDC, 2013; Table 30: 59.
- [2] NCD Statistics for the Pacific Islands Countries and Territories, Secretariat of the Pacific Community. 2011. Available at: http://www.spc.int/hpl/index.php? option=com_content&task=blogcategory&id=23&Itemid=42.
- [3] USAPI Standards for the Management of Tuberculosis and Diabetes. 2012. Available at: http://www.spc.int/tb/en/tb-support/ 75-pacific-standards-for-management-of-tb-and-diabetes.
- [4] WHO Collaborative Framework for Care and Control of Tuberculosis and Diabetes IUATLD TB and DM Guideline Group, TWHO/HTM/TB/2011. Available at: http://whqlibdoc.who.int/publications/2011/9789241502252_eng.pdf.
- [5] The RMI. Census of Population and Housing. February 2012. Available at: http://www.doi.gov/oia/reports/upload/RMI-2011-Census-Summary-Report-on-Population-and-Housing.pdf.

- [6] Ghosh S, Moonan PK, Cowan L, et al. Tuberculosis genotyping information management system: enhancing tuberculosis surveillance in the United States. Infect Genet Evol 2012;12(4):782–8.
- [7] Centers for Disease Control and Prevention. Epi-Info 7. Available at: http: //wwwn.cdc.gov/epiinfo/7/index.htm.
- [8] Lehmann EL. Nonparametrics: statistical methods based on ranks. San Francisco: Holden-Day, Inc.; 1975. p. 23–31.
- [9] Gagneux S, DeRiemer K, Van T, et al. Variable host-pathogen compatibility in Mycobacterium tuberculosis. Proc Natl Acad Sci USA 2006;103:2869–73.
- [10] Jeon C Y, Harries A D, Baker M A, et al. Bi-directional screening for tuberculosis and diabetes: a systematic review. Trop Med Int Health 2010;15:1300–14.
- [11] Dooley K E, Chaisson R E. Tuberculosis and diabetes mellitus: convergence of two epidemics. Lancet Infect Dis 2009;9:737–46.
- [12] Ponce-de-Leon A, Garcia M. Tuberculosis and diabetes in Southern Mexico. Diabetes Care 2004;27:1584–90.
- [13] Englberger L, Marks G C, Fitzgerald M H. Insights on food and nutrition in the Federated States of Micronesia: a review of the literature. Public Health Nutr 2003;6:5–17.
- [14] Hezel F X. The new shape of old island cultures. Honolulu: University of Hawaii Press; 2001.
- [15] Pacific Island Health Officers Association. Declaring a Regional regional State state of Health health Emergency emergency Due due to the Epidemic epidemic of Nonnon-Communicable communicable Diseases diseases in the United States-Affiliated affiliated Pacific Islands. Available at: http://www. pihoa.org/initiatives/policy/ncds.php.
- [16] Harries A D, Lin Y, Satyanarayana S, et al. The looming epidemic of diabetes-associated tuberculosis: learning lessons from HIV-associated tuberculosis. Int J Tuberc Lung Dis 2011;15:1436–44.
- [17] Viney K, Cavanaugh J, Kienene T. Tuberculosis and diabetes mellitus in the Republic of Kiribati: a case-control study. Trop Med Int Health 2015;20:650–7.
- [18] Feleke Y, Abdulkadir J. Presence and clinical features of tuberculosis in Ethiopian diabetic patients. East African Med J 1999;76:361–4.
- [19] Cavanaugh J, Viney K, Kienene T. Effect of diabetes on tuberculosis presentation and outcomes in Kiribati: a case-control study. Trop Med Int Health 2015;20:643–9.
- [20] Aleksic E, Merker M, Cox H, Reiher B, Sekawi Z, et al. First molecular epidemiology study of Mycobacterium tuberculosis in Kiribati. PLoS ONE 2013;8(1).
- [21] Leung C, Lam T. Diabetic control and risk of Tuberculosis: a cohort Study. Am I Epidemiol 2008;167:1486–94.
- [22] Baker M, Lin H, Chang H, Murray M. The risk of tuberculosis disease among persons with diabetes mellitus: a prospective cohort study. Clin Infect Dis 2012;54(6):818.
- [23] Diel R, Loddenkemper R, Nienhaus A. Evidence-based comparison of commercial interferon-gamma release assays for detecting active TB: a metaanalysis. Chest 2010;137(4):952–68.
- [24] Riza A, Pearson F, Ugarte-Gil B. Clinical management of concurrent diabetes and tuberculosis and the implications for patient services. Lancet Diabetes Endocrinol 2014;2:740–52.